Visual clue to new Parkinson's disease therapies

Immunohistochemistry for alpha-synuclein showing positive staining (brown) of an intraneural Lewy-body in the Substantia nigra in Parkinson's disease. Credit: Wikipedia

A biologist and a psychologist at the University of York have joined forces with a drug discovery group at Lundbeck in Denmark to develop a potential route to new therapies for the treatment of Parkinson's Disease (PD).

Dr Chris Elliott, of the Department of Biology, and Dr Alex Wade, of the Department of Psychology, have devised a technique that could both provide an of the disease and result in therapies to mitigate its symptoms.

In research reported in Human Molecular Genetics, they created a more sensitive test which detected neurological changes before degeneration of the nervous system became apparent.

In laboratory tests using , the researchers discovered that a human genetic mutation that causes Parkinson's amplified visual signals in young flies dramatically. This resulted in loss of vision in later life.

Working with researchers from the Danish pharmaceutical company, H.Lundbeck A/S, they tested a new drug that targets the Parkinson's mutation in flies. This drug prevented the abnormal changes in the flies' visual function.

It is the first time that the compound has been used in vivo and its effectiveness was analysed using the new, sensitive technique devised by Dr Wade. This was originally used for measuring vision in people with eye disease and epilepsy.

Dr Elliott, who is part-funded by Parkinson's UK, said: "If this kind of drug proves to be successful in clinical trials, it would have the potential to bring long-lasting relief from PD symptoms and fewer side effects than existing levadopa therapy."

Dr Wade added: "This technique forms a remarkable bridge between human clinical science and animal research. If it proves successful in the future, it could open the door to a new way of studying a whole range of neurological diseases."

Senior Vice President, Research at Lundbeck, Kim Andersen, said: "This new research may prove to be groundbreaking in the understanding and treatment of Parkinson's disease. Science does not currently have answers for what happens in the brain before and during the disease, but these discoveries may bring us closer to this understanding. This may also give us the opportunity to revolutionize the diagnosis and treatment of Parkinson's disease, for the benefit of patients and their families."

More information: The paper 'Abnormal visual gain control in a Parkinson's Disease model' is published in Human Molecular Genetics hmg.oxfordjournals.org/content… 014/04/08/hmg.ddu159

Related Stories

Treating depression in Parkinson's patients

date Apr 18, 2014

A group of scientists from the University of Kentucky College of Medicine and the Sanders-Brown Center on Aging has found interesting new information in a study on depression and neuropsychological function in Parkinson's ...

Researchers investigating genetics of Parkinson's disease

date Mar 11, 2014

(Medical Xpress)—Researchers at Emory University School of Medicine will study individuals with genetic mutations associated with Parkinson's disease (PD) as part of the Parkinson's Progression Markers Initiative (PPMI), ...

Recommended for you

Apple highlights Parkinson's app

date Mar 10, 2015

A new iPhone mobile app which allows patients with Parkinson's disease to track their symptoms in real time and share this information with researchers was featured by Apple executives today during the company's ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.